After building expectations, the UK’s life sciences plan falls short of the hype
Merck’s recent announcement of a new research center in London likely whetted the UK life sciences sector’s appetite for even bigger news from the government’s new industry plan, out today. But despite a considerable amount of loyal cheering about post-Brexit preparations, it doesn’t amount to nearly enough to tip the economic scales in biopharma’s favor.
And to be fair, what kind of official economic development plan, salted with corporate projects, can do that, anyway?
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.